Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.31 |
| ▸ | ITGAV | P06756 | 7/20 | 0.31 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156657 | 0.78 | ALDH1A1 (0.37) | ALDH1A1HRH3 | |
| SCHEMBL1483113 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MEN1MAPTKMT2AL3MBTL1 | |
| SCHEMBL4410585 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL12334338 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL4402037 | 0.75 | HRH3 (0.38) | HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL6948618 | 0.74 | HRH3 (0.37) | ALDH1A1HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL17966443 | 0.74 | ITGB3 (0.39) | ALDH1A1HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL31420767 | 0.74 | HRH3 (0.37) | HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL10417796 | 0.74 | ITGB3 (0.39) | ALDH1A1HRH3ITGB3ITGAVITGB5 | |
| SCHEMBL417814 | 0.74 | HRH3 (0.37) | ALDH1A1HRH3ITGB3ITGAVITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017155-A1 | SLEEP IMPROVING AGENT | Amino Up Co., Ltd. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20200246335-A1 | SLEEP IMPROVING AGENT | AMINO UP CHEMICAL CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-20190201395-A1 | SLEEP IMPROVING AGENT | AMINO UP CHEMICAL CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3466427-A1 | SLEEP IMPROVING AGENT | Amino Up Chemical Co., Ltd. (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-1562901-B1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7476681-B2 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION (US) | 2009-01-13 | — | — | US | disclosed |
| US-7074795-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060148816-A1 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | SCHERING CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1562901-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040127503-A1 | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004046111-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201395-A1 | SLEEP IMPROVING AGENT | HSF1, HSPH1, HSPA2 | ALDH1A1 1443/4885HRH3 151/4885CXCR4 4187/4885 |
| US-20060148816-A1 | anticarcinogenic agent; prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia, or polycystic ovary syndrome, prostate, lung, pancreatic, colon, renal cancer, myeloid leukemia | HSD3B1, HSD17B3, HSD3B2 | ALDH1A1 144/4885HRH3 2874/4885CXCR4 3740/4885 |
| US-20040127503-A1 | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | HSD17B3, HSD17B1, HSD17B11 | ALDH1A1 96/4885HRH3 3802/4885CXCR4 4455/4885 |
| US-20230017155-A1 | SLEEP IMPROVING AGENT | HSF1, HSPH1, HSPA2 | ALDH1A1 1345/4885HRH3 267/4885CXCR4 4584/4885 |
| US-20200246335-A1 | SLEEP IMPROVING AGENT | HSF1, HSPH1, HSPA2 | ALDH1A1 1443/4885HRH3 151/4885CXCR4 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.